50% Gains Are Possible For This $7B Medtech Stock
A leader in diagnostic testing looks attractive after sell-off
Highlights:
This business exploded during the pandemic thanks to COVID testing revenue. But the business was performing well before then.
With COVID revenue bottoming, strength in a historically attractive business is about to shine through.
We think the stock has 50% upside in a conservative scenario, making it more than worth the risk near the lows.
Keep reading with a 7-day free trial
Subscribe to Overlooked Alpha to keep reading this post and get 7 days of free access to the full post archives.